Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

Deborah A. Bradley, Stephanie Daignault, Charles J. Ryan, Robert S. DiPaola, Kathleen A. Cooney, David C. Smith, Eric Small, Paul Mathew, Mitchell E. Gross, Mark N. Stein, Alice Chen, Kenneth J. Pienta, June Escara-Wilke, Gerald Doyle, Mahmoud Al-Hawary, Evan T. Keller, Maha Hussain

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)1517-1518
Number of pages2
JournalInvestigational New Drugs
Volume29
Issue number6
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Bradley, D. A., Daignault, S., Ryan, C. J., DiPaola, R. S., Cooney, K. A., Smith, D. C., Small, E., Mathew, P., Gross, M. E., Stein, M. N., Chen, A., Pienta, K. J., Escara-Wilke, J., Doyle, G., Al-Hawary, M., Keller, E. T., & Hussain, M. (2011). Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs, 29(6), 1517-1518. https://doi.org/10.1007/s10637-010-9502-7